Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00337428
Status:
COMPLETED
Last Update Posted:
2016-11-16
First Post:
2006-06-14
Brief Title:
Concomitant Use of Gardasil V501 Human Papillomavirus Types 6 11 16 18 Recombinant Vaccine With Combined Diptheria Tetanus Pertussis and Poliomyelitis Vaccine in Adolescents V501-024COMPLETED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
An Open-Label Randomized Multicenter Study of the Safety Tolerability and Immunogenicity of Gardasil V501 Given Concomitantly With REPEVAX in Healthy Adolescents 11-17 Years of Age
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Data from this study are expected to demonstrate that Gardasil V501 Human Papillomavirus Types 6 11 16 18 Recombinant Vaccine when administered concomitantly with a combined diphtheria tetanus pertussis and poliomyelitis vaccine in adolescents remains immunogenic and well-tolerated and it does not impair the immunogenicity of the concomitant vaccines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_093 | None | None | None |